Caas Capital Management LP Crinetics Pharmaceuticals, Inc. Transaction History

Caas Capital Management LP

  • $288 Million
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$16.88 - $25.23 $2.81 Million - $4.2 Million
-166,317 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$15.9 - $21.15 $2.64 Million - $3.52 Million
166,317 New
166,317 $3.14 Million
Q4 2020

Feb 12, 2021
SELL
$12.08 - $17.46 $432,367 - $624,928
-35,792 Closed
0 $0
Q3 2020

Nov 09, 2020
SELL
$13.62 - $17.66 $1.11 Million - $1.44 Million
-81,622 Reduced 69.52%
35,792 $561,000
Q2 2020

Aug 14, 2020
BUY
$13.04 - $23.23 $1.53 Million - $2.73 Million
117,414 New
117,414 $2.06 Million

Others Institutions Holding CRNX

# of Institutions
244
Shares Held
78.2M
Call Options Held
268K
Put Options Held
197K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.73B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email